Southern Implants, (Pty.) Ltd. – FDA Warning Letter, Oct 7, 2010

On October 4-7, 2010, an FDA inspection of Southern Implants (Pty.) Ltd. in Irene, South Africa, revealed that their Dental Implant Devices and Accessories were adulterated under 21 U.S.C. 351(h) due to non-conformity with Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) regulation (21 C.F.R. Part 820).

Key violations included: 1. **Failure to establish and maintain adequate CAPA procedures (21 CFR 820.100(a))**: Inadequate monitoring of quality data sources (e.g., customer complaints, nonconformances), insufficient specificity in analyses, and lack of documented root cause investigations and corrective actions for identified issues (e.g., incorrect product labeling, mislabeled healing abutments, inconsistent laser marking procedures). The firm's response was inadequate, lacking documentation of corrections and complete trend analyses. 2. **Failure to establish and maintain adequate design input procedures (21 CFR 820.30(c))**: For Zygomatic implants, the rationale for design requirements (e.g., restorative angle, head diameter, flute dimensions/sharpness) was not documented or justified. The firm's response was inadequate, lacking documentation of complete design requirement implementation. 3. **Failure to control design changes (21